Search hospitals > Iowa > Des Moines
Medical Oncology and Hematology Associates-Des Moines
Claim this profileDes Moines, Iowa 50309
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Ovarian Cancer
323 reported clinical trials
2 medical researchers
Summary
Medical Oncology and Hematology Associates-Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Cancer, Recurrence, Breast Cancer, Adenocarcinoma, Ovarian Cancer and other specialties. Medical Oncology and Hematology Associates-Des Moines is involved with conducting 323 clinical trials across 451 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Recurrence
Global LeaderStage IV
Stage III
Stage I
Top PIs
Joshua LukenbillMedical Oncology and Hematology Associates-Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Tumors
140 reported clinical trials
215 drugs studied
Robert J. BehrensIowa Methodist Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
43 reported clinical trials
97 drugs studied
Clinical Trials running at Medical Oncology and Hematology Associates-Des Moines
Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lung Cancer
Prostate Cancer
Gastric Cancer
Bladder Cancer
Diffuse Large B-Cell Lymphoma
Pancreatic Cancer
Reduced-Intensity Chemoradiation
for Anal Cancer
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
Recruiting3 awards Phase 25 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Medical Oncology and Hematology Associates-Des Moines?
Medical Oncology and Hematology Associates-Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Cancer, Recurrence, Breast Cancer, Adenocarcinoma, Ovarian Cancer and other specialties. Medical Oncology and Hematology Associates-Des Moines is involved with conducting 323 clinical trials across 451 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.
Where is Medical Oncology and Hematology Associates-Des Moines located?
Medical Oncology and Hematology Associates-Des Moines is situated at 1221 Pleasant St, Suite 100, Des Moines, IA 50309, conveniently located near the center of Des Moines.
Who should I call to ask about financial aid or insurance network?
At Medical Oncology and Hematology Associates, patients have access to financial counselors during their initial visits and whenever they have inquiries about their account or insurance coverage. These counselors are insurance experts ready to answer questions and confirm that a coverage plan is in place before treatment starts. They can also provide information on patient assistance programs and payment options.
What insurance does Medical Oncology and Hematology Associates-Des Moines accept?
Medical Oncology & Hematology Associates in Des Moines, IA, accepts all insurance plans. Patients must have an updated insurance card on file. Copayments, deductibles, and coinsurance are due at each visit, with any charges not covered by insurance being the responsibility of the patient or guarantor.
What awards or recognition has Medical Oncology and Hematology Associates-Des Moines received?
Medical Oncology and Hematology Associates-Des Moines, located in Des Moines, Iowa, is celebrated for its contributions to cancer research and patient care. The hospital has been actively involved in clinical trials with prestigious research groups, including the Mayo Clinic Cancer Center’s North Central Cancer Treatment Group, Eastern Cooperative Oncology Group, Southwest Oncology Group, and National Surgical Adjuvant Breast and Bowel Project. It has also been at the forefront of adjuvant therapies for colon and rectal cancers for over twenty years and registered the first patient for a clinical trial under Vice President Joe Biden’s Cancer Moonshot initiative.